EyePoint Pharmaceuticals Enters Material Definitive Agreement
Ticker: EYPT · Form: 8-K · Filed: Oct 17, 2025 · CIK: 1314102
| Field | Detail |
|---|---|
| Company | Eyepoint Pharmaceuticals, Inc. (EYPT) |
| Form Type | 8-K |
| Filed Date | Oct 17, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $12.00, $11.999, $141 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement
Related Tickers: EYPT
TL;DR
EYPT signed a big deal, details to come.
AI Summary
EyePoint Pharmaceuticals, Inc. announced on October 14, 2025, the entry into a material definitive agreement. The company, formerly known as pSivida Corp. and pSivida LTD, is incorporated in Delaware and headquartered in Watertown, MA.
Why It Matters
This filing indicates a significant new contract or partnership for EyePoint Pharmaceuticals, which could impact its future business operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the specifics of which are not yet detailed in this initial filing.
Key Players & Entities
- EyePoint Pharmaceuticals, Inc. (company) — Registrant
- pSivida Corp. (company) — Former company name
- pSivida LTD (company) — Former company name
- October 14, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Watertown, MA (location) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by EyePoint Pharmaceuticals?
The filing states that EyePoint Pharmaceuticals, Inc. entered into a material definitive agreement on October 14, 2025, but the specific details of the agreement are not provided in this initial 8-K filing.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on October 14, 2025.
What were EyePoint Pharmaceuticals' former company names?
EyePoint Pharmaceuticals, Inc. was formerly known as pSivida Corp. and pSivida LTD.
In which state is EyePoint Pharmaceuticals, Inc. incorporated?
EyePoint Pharmaceuticals, Inc. is incorporated in Delaware.
Where are EyePoint Pharmaceuticals, Inc.'s principal executive offices located?
EyePoint Pharmaceuticals, Inc.'s principal executive offices are located at 480 Pleasant Street, Watertown, MA 02472.
Filing Stats: 1,350 words · 5 min read · ~5 pages · Grade level 11.6 · Accepted 2025-10-16 18:10:15
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 EYPT The Nasdaq Global Market Indi
- $12.00 — blic for the Shares in the Offering was $12.00 per Share and the price to the public f
- $11.999 — public for the Pre-Funded Warrants was $11.999 per Pre-Funded Warrant, which represent
- $141 m — ny from the Offering were approximately $141 million, after deducting underwriting dis
Filing Documents
- d98837d8k.htm (8-K) — 33KB
- d98837dex11.htm (EX-1.1) — 247KB
- d98837dex41.htm (EX-4.1) — 83KB
- d98837dex51.htm (EX-5.1) — 12KB
- d98837dex991.htm (EX-99.1) — 13KB
- d98837dex992.htm (EX-99.2) — 15KB
- g98837g1016012428827.jpg (GRAPHIC) — 2KB
- g98837g1016013038689.jpg (GRAPHIC) — 4KB
- g98837g1016021606698.jpg (GRAPHIC) — 3KB
- 0001193125-25-241639.txt ( ) — 634KB
- eypt-20251014.xsd (EX-101.SCH) — 3KB
- eypt-20251014_lab.xml (EX-101.LAB) — 17KB
- eypt-20251014_pre.xml (EX-101.PRE) — 11KB
- d98837d8k_htm.xml (XML) — 3KB
Forward Looking Statements
Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements that involve estimates, assumptions, risks and uncertainties. Forward-looking statements include, but are not limited to, statements related to the Offering and the use of proceeds from the Offering. The risks and uncertainties relating to the Company and the Offering include general market conditions, as well as other risks detailed from time to in the Company's Securities and Exchange Commission filings, including in its Annual Report on Form 10-K for the year ended December 31, 2024, its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, its Current Reports on Form 8-K and the prospectus supplement dated October 14, 2025 relating to the Offering. These documents contain important factors that could cause actual results to differ from current expectations and from forward-looking statements contained in this Current Report on Form 8-K. These forward-looking statements speak only as of the date of this Current Report on Form 8-K and the Company undertakes no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this Current Report on Form 8-K. Item8.01. Other Events. The Company issued press releases announcing the launch and pricing of the Offering on October 14, 2025, and October 14, 2025, respectively. Copies of these press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, and are each incorporated herein by reference. Item9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 1.1 Underwriting Agreement, dated October 14, 2025, by and among EyePoint Pharmaceuticals, Inc. and J.P. Morgan Securities LLC, Jefferies LLC, Citigroup Global Markets Inc. and Guggenheim Securities, LLC 4.1 Form of Pre-Funded Warrant to Purchase Commo
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYEPOINT PHARMACEUTICALS, INC. Date: October 16, 2025 /s/ George O. Elston George O. Elston Executive Vice President and Chief Financial Officer